Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
Retrieved on:
Wednesday, August 31, 2022
Medical Devices, Health, Biometrics, Clinical Trials, Pharmaceutical, Biotechnology, Software, Inflammation, Patient, HRCT, Technology, Pharmacokinetics, SLP, Research, Solution, Glossary of biology, AAPS, LinkedIn, Biophysical environment, Risk, Systemic scleroderma, Chronic endothelial injury hypothesis, GGO, Economics, Prognosis, Simulations Plus, Scleroderma, ECM, U.S. Securities and Exchange Commission, RO, Mission statement, Fibrosis, Nasdaq, Company, HC, FDA, Biotechnology, Element, Population, Biomarker, ESG, Extracellular matrix, Drug discovery, Private Securities Litigation Reform Act, Drug development, QSP, ILD, DSS, Pharmaceutical industry, Medical device, Risk management
Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released ILDsym version 1A, quantitative systems pharmacology (QSP) modeling software.
Key Points:
- Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released ILDsym version 1A, quantitative systems pharmacology (QSP) modeling software.
- Dr. Lisl Shoda , associate vice president, added: Interstitial lung disease significantly worsens the prognosis for patients with SSc and increases their healthcare costs by roughly 50%.
- ILDsym and our scientific consulting expertise are positioned to support our clients in the development of novel treatments for SScILD.
- Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions.